Viridian Therapeutics said Tuesday that an experimental treatment improved the signs and symptoms of thyroid eye disease — results that achieved the primary goals of a Phase 3 clinical trial and compared favorably to a similar drug already approved and sold by Amgen.
In the 15-week study, 70% of participants responded to treatment with Viridian’s drug called VRDN-001, compared to 5% in the placebo group. Response was defined as a meaningful reduction in eye bulging, a hallmark sign of thyroid eye disease.
The study, called THRIVE, enrolled 113 participants with active thyroid eye disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
